The workday is moving briskly along, and Eden Miller has just enough time for a quick call. “I do have another meeting in about 10 minutes,” the doctor of osteopathic medicine said. She won’t need even that long to make clear why the latest batch of real-world data on the FreeStyle Libre portfolio — including one in which Miller was a lead investigator — are so significant for people with type 2 diabetes using insulin — and for those who aren’t. “There’s this presumption that in order to benefit from CGM — or even to be eligible for CGM — you have to be taking multiple daily injections or that they’re the only people who benefit,” Miller said. “It’s kind of like saying, ‘Only people who speed or have speeding tickets need speedometers in their cars. The reality is that all persons living with diabetes — those with multiple daily shots or one shot of insulin per day or individuals who aren’t taking insulin — can significantly benefit from the information that FreeStyle Libre can provide. Imagine if we were trying to effectively drive our car without speedometers. We just wouldn’t know.” The evidence is quick to back Miller’s assertions. In data1 presented at the American Diabetes Association (ADA) 80th Scientific Sessions, the FreeStyle Libre system was found to offer: Significant reduction in hemoglobin A1c (HbA1c) among people with type 2 diabetes for both long-acting insulin and non-insulin users, results that are similar to those typically seen when adding insulin to treatment regimens. Specifically, FreeStyle Libre users saw a 0.8% drop (from 8.5% to 7.7%) after six months and 0.6% drop (from 8.5% to 7.9%) after one year. Moreover, the greatest HbA1c decreases were seen among non-insulin users with type 2 diabetes, including a 0.9% reduction at six months and 0.7% drop after 12 months. Those clinically significant reductions brought them closer to the ADA's recommended A1c goal of 7% for adults with diabetes.2 Simply, people may be able to manage their glucose levels with CGM technology instead of adding insulin to their treatment regimens.